-0.4 C
New York

LLY Stock plunges after ‘bump in the road’ shakes up its new diabetes drug

New Diabetes Drug

Eli Lily (LLY) has experienced a “hiccup in the road” for its new diabetes treatment, Mounjaro, an analyst said Thursday as LLY shares tumbled.

Mounjaro’s sales came in at $279.2 million, missing expectations of $288-370 million, according to various analyst calls. Lilly’s slides indicate Mounjaro is now covered for about 50% of Commercial Insurance and Medicare Part D beneficiaries, up from just 45% in the third quarter, SVB Securities analyst David Risinger said in a note. to customers.

Additionally, sales of Lilly’s largest diabetes drug, Trulicity, were also lower than expected at $1.94 billion, although they were up 3%. Analysts expected $2.07 billion to close to $2.1 billion, Risinger said.

But Edward Jones analyst John Boylan says the fall in LLY shares is an overreaction. He notes that Lilly is also testing Mounjaro as a treatment for obesity, sleep apnea, and other diabetes-related illnesses. Ahead of today’s stock market opening, Lilly shares fell 5.7% near 323.20.

“Demand remains strong for Trulicity and Lilly had issues keeping up with orders,” he said in a note. “We believe the same is true for Mounjaro. As manufacturing capacity for these key products increases, this issue will likely dissipate.”

He added: “The results for this quarter can be seen as a bump in the road.”

Stock LLY: Covid antibodies weigh on sales

Overall fourth-quarter sales fell 9% to $7.3 billion as Lilly’s Covid antibody revenue took a huge hit. Excluding the impact, sales were actually up 5%, Lilly said in a press release. Sales were a hair below expectations at $7.33 billion, according to FactSet.

Adjusted earnings fell 4% to $2.09 per share, but easily beat expectations between $1.78 and $1.87. SVB’s Risinger noted that Lilly experienced a much lower tax rate than expected, which helped support adjusted earnings of 15 cents per share.

Breast cancer drug Verzenio posted the best growth, doubling year-over-year to $808 million. That was well over forecast by $706 million to $725 million, he said. On the other hand, Lilly’s Covid antibody revenue fell 96% to $38 million. Although stock analysts at LLY were expecting a drop, it was much steeper than the $102-200 million sell calls.

Lilly raised its earnings outlook for the year to $8.35 – $8.55 per share, less certain items. Analysts were expecting $8.35 per share. The company maintained its sales forecast of $30.3 billion at $30.8 billion, in line with LLY stock analysts’ forecast for $30.47 billion.

LLY stock recently slipped below a flat bottom with a buy point of 375.35, according to MarketSmith.com.

Follow Allison Gatlin on Twitter at @IBD_AGatlin.


Thermo Fisher unveils bullish outlook as Boston Scientific gains on the online report

AbbVie’s two-decade Humira monopoly ends with Amgen’s 55% counterfeit

Looking for the next big winners in the stock market? Start with these 3 steps

Receive timely buy and sell alerts with IBD Ranking

Watch the IBD Investment Strategies Show for actionable market insights

Related Articles


Please enter your comment!
Please enter your name here

Stay Connected


Latest Articles